Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of new antidepressants

A Sambunaris1, J K Hesselink, R Pinder

  • 1Department of CNS Research, Solvay Pharmaceuticals, Marietta, Ga., USA.

The Journal of Clinical Psychiatry
|January 1, 1997
PubMed
Summary

Novel antidepressants often target multiple neurotransmitter receptors, combining mechanisms for better efficacy and fewer side effects. This "designer polypharmacy" approach, exemplified by mirtazapine, enhances antidepressant treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pharmacodynamic effects of combined administration of flibanserin and alcohol.

Journal of clinical pharmacy and therapeutics·2017
Same author

Ulnar Shortening Osteotomy: Are Complications Under Reported?

Journal of hand and microsurgery·2015
Same author

Osteomyelitis of the hand.

The Journal of hand surgery, European volume·2015
Same author

Lifetime exposure to estrogens and Parkinson's disease in California teachers.

Parkinsonism & related disorders·2014
Same author

Cloning of the δ-aminolevulinic acid synthase structural gene in yeast.

Current genetics·2013
Same author

Innovative solutions to novel drug development in mental health.

Neuroscience and biobehavioral reviews·2013

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Numerous novel antidepressants targeting diverse neurotransmitter receptors are in clinical development.
  • Many emerging antidepressants feature dual mechanisms of action, affecting multiple neurotransmitter systems.
  • Mirtazapine exemplifies a strategy of simultaneously modulating both serotonergic and noradrenergic systems.

Purpose of the Study:

  • To review the development of novel antidepressants with dual mechanisms of action.
  • To highlight the therapeutic potential of targeting multiple neurotransmitter receptors.
  • To discuss the principles of rational polypharmacy in antidepressant design.

Main Methods:

  • Review of clinical evaluations for novel antidepressant agents.

Related Experiment Videos

  • Analysis of the mechanisms of action of emerging antidepressants.
  • Examination of mirtazapine's pharmacological profile.

    • Main Results:

    • Most new antidepressants exhibit dual or multiple mechanisms of action.
    • Mirtazapine's alpha 2 antagonism enhances serotonin and norepinephrine release.
    • Mirtazapine's serotonin-2 and serotonin-3 antagonism mitigates SSRI-associated side effects.

    Conclusions:

    • The "designer polypharmacy" approach rationally combines pharmacologic actions.
    • Simultaneous targeting of neurotransmitter systems can enhance antidepressant efficacy.
    • This strategy aims to improve the tolerability of novel antidepressant treatments.